Do adalimumab, colchicine, deflazacort, apremilast, or telmisartan interact with paracetamol, pantoprazole, or domperidone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Drug Interactions with Paracetamol, Pantoprazole, and Domperidone

None of the listed medications (adalimumab, colchicine, deflazacort, apremilast, or telmisartan) have clinically significant interactions with paracetamol, pantoprazole, or domperidone that would require dose adjustments or avoidance.

Detailed Analysis by Drug

Telmisartan

No clinically significant interactions exist. FDA labeling explicitly states that co-administration of telmisartan did not result in clinically significant interactions with acetaminophen (paracetamol) 1. Telmisartan is not metabolized by cytochrome P450 enzymes and shows only minimal CYP2C19 inhibition, making interactions with pantoprazole (a CYP2C19 substrate) negligible.

Paracetamol (Acetaminophen)

Paracetamol has remarkably few clinically significant drug interactions at therapeutic doses 2. The primary concern is potentiation of hepatotoxicity in overdose situations with enzyme-inducing drugs, which does not apply to any of your listed medications. None of the drugs you've listed are enzyme inducers that would affect paracetamol metabolism.

Pantoprazole

Pantoprazole demonstrates a low potential for drug interactions compared to other proton pump inhibitors 3, 4. Studies show pantoprazole does not affect the pharmacokinetics of numerous medications including diazepam, diclofenac, digoxin, warfarin, and others 4. Neither colchicine, adalimumab, deflazacort, apremilast, nor telmisartan are substrates significantly affected by pantoprazole's minimal CYP450 effects.

Domperidone

The combination of domperidone with paracetamol has been studied directly and found to be safe, with no significant adverse events reported 5. None of your listed medications have documented interactions with domperidone.

Colchicine

While colchicine has important interactions with CYP3A4 and P-glycoprotein inhibitors [6, @1-5@], neither paracetamol, pantoprazole, nor domperidone are significant inhibitors of these pathways. The extensive literature on colchicine interactions focuses on strong CYP3A4/P-gp inhibitors (like clarithromycin, cyclosporine) and statins—none of which apply here.

Adalimumab, Deflazacort, and Apremilast

These medications lack documented interactions with paracetamol, pantoprazole, or domperidone in available literature 7, 8. As biologics (adalimumab) and immunomodulators (apremilast, deflazacort), they do not share metabolic pathways that would create interactions with these commonly used medications.

Clinical Bottom Line

All five medications can be safely co-administered with paracetamol, pantoprazole, and domperidone without dose adjustments. The only caveat is standard monitoring for each drug's individual adverse effects, but no additional monitoring is required due to drug-drug interactions with this specific combination.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.